Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972044 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
A Phase 3 study, sponsored by Axsome Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 516
- Enrollment target
NCT05972044 is a Phase 3 study that has completed, run by Axsome Therapeutics. The registered enrollment target is 516 participants.
The verdict
NCT05972044, a Phase 3 study, has completed, sponsored by Axsome Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 516 participants
- Enrollment target
Study Summary
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.
Interventions
- DRUG Placebo
- DRUG Solriamfetol 150 mg
- DRUG Solriamfetol 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 516 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2025-03-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05972044
The ClinicalTrials.gov registry entry for NCT05972044 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 516 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05972044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05972044 about?
NCT05972044 is a clinical study titled "A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)". FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.
What is the current status of trial NCT05972044?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 516 participants. The study started on 2023-07-06. Estimated completion is 2025-03-14.
What interventions are being tested in trial NCT05972044?
The interventions under investigation include: Placebo (DRUG), Solriamfetol 150 mg (DRUG), Solriamfetol 300 mg (DRUG).
Who is sponsoring clinical trial NCT05972044?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.